Patents
Literature
Patsnap Copilot is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Patsnap Copilot

187 results about "Fibrinolysis" patented technology

Fibrinolysis is a process that prevents blood clots from growing and becoming problematic. This process has two types: primary fibrinolysis and secondary fibrinolysis. The primary type is a normal body process, whereas secondary fibrinolysis is the breakdown of clots due to a medicine, a medical disorder, or some other cause.

Bacterial strain LT3 producing alkalescence cellulase and breeding method and initial optimization of cellulase production conditions thereof

InactiveCN101555461AAlkaline resistantAdapt to a wide range of pHBacteriaMicrobiological testing/measurementBacillus cereusCellulase
The invention provides a bacterial strain LT3 producing alkaline cellulose and a breeding method and an initial optimization of cellulose production conditions thereof. The bacterial strain LT3 with higher secretory volume of alkaline cellulose is obtained by steps of conducting accumulation culture, separation and purification, identification of Congo red dye and liquid fermentation on samples obtained from rotten wood or nearby soil thereof; the bacterial strain is identified to be bacillus cereus by initial identification, sequence clone and phylogenetic analysis; and 16s and r DNA sequences are shown as sequence list SEQ ID NO.1. The invention has potential theoretical and application values for research on the action mechanism of the alkaline cellulose and the production of the alkaline cellulose preparation; and the bacterial strain LT3 of the alkaline cellulose can produce the alkaline cellulose of single component and is convenient for separation and purification, thus being an ideal material for gene clone of the alkaline cellulose and having potential theoretical and practical significances for constructing alkaline cellulose fibrinolysis engineered bacterial strain and questing the action mechanism of the alkaline cellulose, and the method is simple, fast and easy for implementation.
Owner:FUZHOU UNIV

Blood coagulation factor and fibrinolysis measuring method

The invention relates to a blood coagulation factor and fibrinolysis measuring method, which is used for testing by using a semi-automatic blood coagulation analyzer. The blood coagulation factor and fibrinolysis measuring method comprises the following testing steps of: collecting a patient blood sample and separating blood plasma out; injecting the blood plasma into a testing cup by using a sample feeding gun; putting the testing cup in a blood coagulation factor measuring device, adding a reagent, starting a timing button of the blood coagulation factor testing device, and testing the blood plasma in the testing cup by the blood coagulation factor testing device according to a double magnetic circuit magnetic bead method; and injecting the blood plasma into a fibrinolysis testing cup by the sample feeding gun, putting the fibrinolysis testing cup in a fibrinolysis testing device, adding a reagent, starting a timing button of the fibrinolysis testing device, testing the blood plasmain the fibrinolysis testing cup by the fibrinolysis testing device according to a photoelectric turbidimetry, and printing and outputting fibrinolysis data after the testing by the fibrinolysis testing device is ended. The blood coagulation factor and fibrinolysis measuring method disclosed by the invention is simple and convenient and greatly reduced in cost.
Owner:BEIJING PRECIL INSTR CO LTD

Traditional Chinese compound for curing central obesity and nonalcoholic fatty liver disease and preparation method thereof

InactiveCN101530517AReduce abdominal circumferenceReduced CT ratioMetabolism disorderDigestive systemInflammatory factorsTreatment effect
The invention discloses a traditional Chinese compound preparation for curing nonalcoholic fatty liver and central obesity and is characterized in that the compound preparation is prepared by adding medicinal excipient to the extractives of milk veteh, rhizoma coptidis, prepared rhubarb, raw cattail pollen and herba artemisiae capillaris, wherein the weight mixture ratio of milk veteh, rhizoma coptidis, prepared rhubarb, raw cattail pollen and herba artemisiae capillaris is 1-4:1:1-3:1-3:1-3. Proved by clinical trial, the drug combination of the invention can reduce the abdominal perimeter of patients, lower the AUC (area under curve) of triglyceride after dinner, improve the CT specific value of liver and spleen and bring down the transaminase level of liver with evident treatment effect. Verified by clinical research, the compound can obviously increase the insulin sensitivity of patients, lower inflammatory factor level and improve fibrinolysis-blood clotting function. Shown by experimental research, the drug of the invention can enhance the sensitivity of fat and muscle cells to insulin and has significant value in treating nonalcoholic fatty liver and central obesity which take insulin resistance as fundamental pathological link.
Owner:王文健

Strains with high cellulase activity as well as screening method and use method of strains

The invention relates to the field of wine making, and particularly relates to strains with high cellulase activity as well as a screening method and a use method of the strains. The strains with high cellulase activity are aspergillus. The screening method comprises the following steps of: A. enriching and cultivating bacteria through an inorganic salt culture medium; B. carrying out once or multiple-time inoculation on the bacteria enriched and cultivated on filter paper dipped with the inorganic salt culture medium; C. acquiring a cultured product at the fracture part of the filter paper, and carrying out once or multiple-time streaking on the cultured product on a carboxymethylcellulose culture medium plate, so as to obtain pure strains; D. cultivating the pure strains obtained from the step C in the inorganic salt culture medium and carrying out fibrinolysis on the cultivated pure strains; E. inoculating the pure strains with high fibrinolysis capacity in the step D to a steriled solid fermentation medium for cultivating; and F. extracting coarse enzyme liquid by adopting a water bath method, and carrying out enzyme activity test to obtain the strains with high cellulase activity. The strains and bread yeast are compounded for use and fermented by taking wine waste lees and brans as main materials. With the adoption of the strains with high cellulase activity, the fermentation rate of the wine waste lees can be improved.
Owner:GUIZHOU MOUTAI WINERY GRP XIJIU CO LTD

Traditional Chinese medicine preparation for purifying blood

The invention discloses a traditional Chinese medicine preparation for purifying blood, which comprises the following components: hawthorn, Astragalus root, leech, cortex moutan, safflower, hemlock parsley, suberect spatholobus stem, vinegar-radix paeoniae alba, angelica, trogopterus dung, salviae miltiorrhizae, propolis, calendula officinalis root, ginkgo leaf and gynostemma pentaphylla. The traditional Chinese medicine composite has the obvious effect of reducing blood lipid, can promote the decomposition of blood lipid, reduces blood viscosity, and resists atherosclerosis; the traditional Chinese medicine composite has the obvious effects of anticoagulation and anti-thrombosis, can inhibit the aggregation of thrombocyte, improves the activity of plasmin, and promotes fibrinolysis; the traditional Chinese medicine composite has favorable effects of heart strengthening, decompression and arrhythmia resistance, can slow heart rate, dilates coronary artery and blood vessel of brain, increases blood flow, lightens myocardial ischemic injury degree, lowers myocardial oxygen consumption, has obvious prevention effect on ischemic cerebrovascular diseases, can dilate peripheral vessel, reduces vascular resistance and promotes blood circulation; and the traditional Chinese medicine composite can promote the generation of haemoglobin and erythrocyte.
Owner:杨勤峰
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products